Verona Pharma (NASDAQ:VRNA) PT Raised to $36.00

Verona Pharma (NASDAQ:VRNA) had its price objective lifted by Piper Sandler from $31.00 to $36.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also issued reports on VRNA. HC Wainwright reissued a buy rating and issued a $32.00 target price on shares of Verona Pharma in a report on Monday, March 4th. Wedbush reissued an outperform rating and issued a $33.00 target price on shares of Verona Pharma in a report on Friday, March 1st. Four equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of Buy and a consensus target price of $33.60.

Verona Pharma Trading Up 2.5 %

Verona Pharma stock opened at $16.20 on Tuesday. The business has a 50-day simple moving average of $16.53 and a two-hundred day simple moving average of $16.08. The company has a market cap of $1.31 billion, a P/E ratio of -23.48 and a beta of 0.41. Verona Pharma has a 52-week low of $11.83 and a 52-week high of $23.81. The company has a quick ratio of 33.33, a current ratio of 33.33 and a debt-to-equity ratio of 0.20.

Verona Pharma (NASDAQ:VRNA) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. Analysts predict that Verona Pharma will post -1.23 EPS for the current year.

Institutional Investors Weigh In On Verona Pharma

A number of institutional investors have recently added to or reduced their stakes in VRNA. Cape Investment Advisory Inc. purchased a new stake in Verona Pharma during the 4th quarter valued at approximately $40,000. BNP Paribas Financial Markets grew its holdings in Verona Pharma by 125.3% during the 4th quarter. BNP Paribas Financial Markets now owns 2,028 shares of the company’s stock valued at $40,000 after buying an additional 1,128 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in Verona Pharma during the 2nd quarter valued at approximately $49,000. Tower Research Capital LLC TRC grew its holdings in Verona Pharma by 950.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,495 shares of the company’s stock valued at $89,000 after buying an additional 4,067 shares in the last quarter. Finally, UBS Group AG grew its holdings in Verona Pharma by 30.3% during the 1st quarter. UBS Group AG now owns 5,432 shares of the company’s stock valued at $109,000 after buying an additional 1,263 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.